Lubazodone
Lubazodone is an experimental antidepressant which was under development by Yamanouchi [Pharmaceutical |Yamanouchi] for the treatment for major depressive disorder in the late 1990s and early 2000s but was never marketed. It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist, and hence has the profile of a antagonist and reuptake inhibitor">receptor antagonist">antagonist and reuptake inhibitor. The drug has good selectivity against a range of other monoamine receptors, with its next highest affinities being for the alpha-1 [adrenergic receptor|α1-adrenergic receptor] and the 5-HT2C receptor. Lubazodone is structurally related to trazodone and nefazodone, but is a stronger serotonin reuptake inhibitor and weaker as a 5-HT2A receptor antagonist in comparison to them and is more balanced in its actions as a SARI. It reached phase II clinical trials for depression, but development was discontinued in 2001 reportedly due to the "erosion of the market in the United States".